-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, China's innovative medicines have been accelerating
.
From 2009, Hengrui Pharmaceuticals became the first Chinese pharmaceutical company to carry out the “Sino-U.
S.
Double Report”, and in 2019, BeiGene's innovative drug Zebutinib was approved for the first time in the United States.
The industry generally believes that Chinese innovative pharmaceutical companies It has gradually embarked on a road of "riding the wind and waves" to go overseas for listing
.
As more and more innovative pharmaceutical companies go overseas, the innovative strength of domestic pharmaceutical companies is also receiving more and more recognition
.
BeiGene BeiGene will be listed in Australia on October 11, BeiGene announced that BeiGene® (Zebutinib) has been approved in Australia for the treatment of mantle cell lymphoma that has received at least one therapy in the past.
(MCL) Adult patients
.
In addition, on October 7th, Baiyueze ® was also approved for the first time in Australia for the treatment of adult patients with Huashi Macroglobulinemia (WM) who have received at least one therapy in the past, or as a first-line Therapies are used to treat patients who are not suitable for chemoimmunotherapy
.
According to the data, Zebutinib is a small molecule inhibitor of Bruton’s tyrosine kinase (BTK) independently developed by BeiGene scientists.
It is currently undergoing extensive clinical trials worldwide as a single drug and other Therapies are combined to treat a variety of B-cell malignancies
.
In addition to Australia, it has previously been approved by the United States and Canada for the treatment of patients with Fahrenheit's macroglobulinemia
.
China Biopharmaceuticals submitted an investigational new drug (IND) application to the FDA.
On October 8, China Biopharmaceuticals issued a corporate announcement stating that the company’s self-developed innovative drug "TCR1672" has been submitted to the U.
S.
Food and Drug Administration (FDA) for trial use.
New drug (IND) application and acceptance
.
According to the announcement, TCR1672 is a second-generation highly selective P2X3 receptor antagonist.
It is currently mainly used in the treatment of refractory chronic cough (RCC) adult patients in the respiratory field and endometriosis in the pain field and other complex internal organs.
Pain patients
.
It is understood that about 5%-10% of adults worldwide suffer from chronic cough
.
But up to now, there is no clinically approved standard drug for the treatment of chronic cough, and there are huge unmet clinical needs
.
In this context, the industry's attention to the innovative drug "TCR1672" independently developed by China Biopharmaceuticals continues to increase
.
Andorra's new anti-cancer drug AND019 has been approved for clinical use in the United States Hangzhou Andorra's third-generation oral breast cancer class 1 new drug AND019, independently developed by Hangzhou Andorra Co.
, Ltd.
, has also recently received clinical approval from the US FDA
.
It is reported that this is another innovative drug approved for global clinical development after the company's new domestic new anemia drug AND017 was approved by the US FDA for Phase II clinical trials earlier this year
.
This also shows that the company has become an international biopharmaceutical company with global development capabilities for new drugs
.
In addition, it is worth mentioning that the preclinical research results of AND019 show that it has excellent in vivo and in vitro biological activity and good oral absorption characteristics
.
At present, there is no oral SERD available in the world
.
Therefore, if it is successfully listed in the future, its market development space is expected to be huge
.
.
From 2009, Hengrui Pharmaceuticals became the first Chinese pharmaceutical company to carry out the “Sino-U.
S.
Double Report”, and in 2019, BeiGene's innovative drug Zebutinib was approved for the first time in the United States.
The industry generally believes that Chinese innovative pharmaceutical companies It has gradually embarked on a road of "riding the wind and waves" to go overseas for listing
.
As more and more innovative pharmaceutical companies go overseas, the innovative strength of domestic pharmaceutical companies is also receiving more and more recognition
.
BeiGene BeiGene will be listed in Australia on October 11, BeiGene announced that BeiGene® (Zebutinib) has been approved in Australia for the treatment of mantle cell lymphoma that has received at least one therapy in the past.
(MCL) Adult patients
.
In addition, on October 7th, Baiyueze ® was also approved for the first time in Australia for the treatment of adult patients with Huashi Macroglobulinemia (WM) who have received at least one therapy in the past, or as a first-line Therapies are used to treat patients who are not suitable for chemoimmunotherapy
.
According to the data, Zebutinib is a small molecule inhibitor of Bruton’s tyrosine kinase (BTK) independently developed by BeiGene scientists.
It is currently undergoing extensive clinical trials worldwide as a single drug and other Therapies are combined to treat a variety of B-cell malignancies
.
In addition to Australia, it has previously been approved by the United States and Canada for the treatment of patients with Fahrenheit's macroglobulinemia
.
China Biopharmaceuticals submitted an investigational new drug (IND) application to the FDA.
On October 8, China Biopharmaceuticals issued a corporate announcement stating that the company’s self-developed innovative drug "TCR1672" has been submitted to the U.
S.
Food and Drug Administration (FDA) for trial use.
New drug (IND) application and acceptance
.
According to the announcement, TCR1672 is a second-generation highly selective P2X3 receptor antagonist.
It is currently mainly used in the treatment of refractory chronic cough (RCC) adult patients in the respiratory field and endometriosis in the pain field and other complex internal organs.
Pain patients
.
It is understood that about 5%-10% of adults worldwide suffer from chronic cough
.
But up to now, there is no clinically approved standard drug for the treatment of chronic cough, and there are huge unmet clinical needs
.
In this context, the industry's attention to the innovative drug "TCR1672" independently developed by China Biopharmaceuticals continues to increase
.
Andorra's new anti-cancer drug AND019 has been approved for clinical use in the United States Hangzhou Andorra's third-generation oral breast cancer class 1 new drug AND019, independently developed by Hangzhou Andorra Co.
, Ltd.
, has also recently received clinical approval from the US FDA
.
It is reported that this is another innovative drug approved for global clinical development after the company's new domestic new anemia drug AND017 was approved by the US FDA for Phase II clinical trials earlier this year
.
This also shows that the company has become an international biopharmaceutical company with global development capabilities for new drugs
.
In addition, it is worth mentioning that the preclinical research results of AND019 show that it has excellent in vivo and in vitro biological activity and good oral absorption characteristics
.
At present, there is no oral SERD available in the world
.
Therefore, if it is successfully listed in the future, its market development space is expected to be huge
.
